lonafarnib has been researched along with 9,10-dimethyl-1,2-benzanthracene in 1 studies
Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (9,10-dimethyl-1,2-benzanthracene) | Trials (9,10-dimethyl-1,2-benzanthracene) | Recent Studies (post-2010) (9,10-dimethyl-1,2-benzanthracene) |
---|---|---|---|---|---|
224 | 34 | 90 | 6,010 | 10 | 772 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, X; Fagin, JA; Johnson, LK; Knauf, JA; Makarewicz, JM | 1 |
1 other study(ies) available for lonafarnib and 9,10-dimethyl-1,2-benzanthracene
Article | Year |
---|---|
Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Cell Line, Tumor; Enzyme Inhibitors; Farnesyltranstransferase; Gene Dosage; Gene Knock-In Techniques; Genes, ras; Humans; Mice, Mutant Strains; Mutation; Papilloma; Piperidines; Pyridines; Skin Neoplasms; Tetradecanoylphorbol Acetate | 2014 |